"That means there is no basis for compounders to make tirzepatide knockoffs," a spokesperson for Lilly told Reuters
Products and their ingredients keep skin healthy and balanced
Plaintiffs in these actions allege that manufacturers, primarily Novo Nordisk and Eli Lilly, failed to adequately warn prescribers and consumers about the risk of NAION and sudden vision loss associated with GLP1 drugs
The role of the thyroid in the control of heart-rate
For readers exploring the diabetes-prevention angle of this same compound, the companion analysis of whether cagrilintide can prevent diabetes in high-risk patients examines the glycemic data in more depth
According to Grand View Research, specifically for GLP-1 weight-loss, the market size in 2025 is about $20.86 billion, expected to grow to $48.84 billion by 2030, with a CAGR of ~18.5%